Raytheon Technologies shares up -11% on ‘surgical innovation’

Raytheun Technology is up 1% to $38.90.

Raytheon shares have climbed about 40% since March and are up about 40%-50% since the beginning of 2017.

The company has a new technology application that is said to be able to help doctors “prevent the spread of cancer.”

“Surgical innovation is a key focus for Raytheons mission to create better treatments and longer lives through new technologies that are designed to be used in combination with existing technologies,” Raytheontech CEO John Lea said in a statement.

Raytheons newest innovation, the “surgical innovations” application, is a device that works like a drill with two wheels that are used to dig a hole.

“We are focused on delivering this technology in a way that allows for the best possible use of existing medical technologies, including our ability to use a precision drill to precisely drill into tumors to remove and isolate them,” Lea added.

In addition to the surgical innovation application, Raytheondech is working on new technologies and “advanced cancer diagnostics,” which can be used to treat a wide variety of cancers.

At the end of March, RayTheon announced that it had a $2.5 billion deal with GE Healthcare to acquire the business of its Advanced Bioinformatics division.

As part of the deal, Ray theon announced a $1.5 million donation to the National Cancer Institute, which is helping to develop new treatments for cancers that were previously understudied.

Since January, Ray Theon has made a lot of headlines with its latest acquisition.

It is reported that Raytheonds latest acquisition, Rayallys new Bioinformatic, has surpassed $200 million in venture funding.

RayTheon has a long history of working on cancer treatments.

It is also one of the largest investors in the healthcare industry.

A large part of that history comes from the work of a team led by Raytheoty and its founder Dr. Joseph Bocci.

Bocci and his team developed a process that uses genetic material and other materials to generate stem cells, which then can be harvested for further development of new drugs and other treatments.

They also developed a new form of cancer screening, the RayTheodys method.

According to RayTheondech, its first clinical trials of the new Raytheonal method in the US are set to begin in 2018.